Featured
-
-
Perspective |
Clinical potential of mass spectrometry-based proteogenomics
Precision medicine approaches to the treatment of cancer are largely reliant on genomic analysis alone. In this Perspective the authors provide a rationale for the incorporation of analysis of the proteome, which is a rich source of biological heterogeneity, into the treatment and management of patients with cancer.
- Bing Zhang
- , Jeffrey R. Whiteaker
- & Amanda G. Paulovich
-
News & Views |
Steps towards effective gynaecological cancer screening
PapSEEK, a novel liquid-based cytology test, enabled the highly specific detection of endometrial and ovarian cancer in a retrospective study. Herein, I discuss potential applications of this tool, both for cancer screening of asymptomatic populations and for the early diagnosis of cancer in symptomatic women.
- Usha Menon
-
-
Review Article |
Epigenome-based cancer risk prediction: rationale, opportunities and challenges
The development of cancer involves several epigenomic alterations, and the presence of certain alterations before the development of cancer is associated with cancer risk. In this Review, the authors describe the potential of epigenomics-based assays to predict an individual's risk of cancer, including discussions of technical, practical and societal issues regarding the implementation of such assays.
- Martin Widschwendter
- , Allison Jones
- & Nora Pashayan
-
Comment |
Bridging the gap: are animal models consistent with clinical cancer cachexia?
Experimental research on cancer-associated cachexia is advancing at an accelerated pace while knowledge of the complex underlying biology of cachexia in humans lags behind. An unmet need exists to accelerate the identification of causal mechanisms in patients with cancer and to determine the parallels between experimental systems and distinct isotypes of human cachexia.
- Vickie E. Baracos
-
Editorial |
Context: the grey matter of cancer
-
-
-
Review Article |
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
The PARP inhibitor olaparib has been approved for clinical use in patients with ovarian cancer withBRCA 1/2 mutations; however, this agent, which can confer substantial improvements in patient survival might also be effective in those without a BRCA mutation. Here, the authors describe the potential for expanding the use of BRCA-mutation testing and PARP inhibition beyond those who are likely to have a BRCAmutation.
- Angela George
- , Stan Kaye
- & Susana Banerjee
-
Review Article |
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Tyrosine kinase inhibitors (TKIs) are the most common agents used for the treatment of patients with chronic myeloid leukaemia (CML). Several agents are available for frontline treatment, or after the development of resistance or intolerance to agents previously used. Herein, the authors evaluate differences between available TKIs, and discuss several end points that can be considered when selecting the first and subsequent lines of treatment of patients with CML.
- Gianantonio Rosti
- , Fausto Castagnetti
- & Michele Baccarani
-
-
-
Review Article |
Development of PI3K inhibitors: lessons learned from early clinical trials
Agents targeting the PI3K/AKT/mTOR pathway have been shown to be safe and effective in treating a number of tumour types. This Review outlines the background to these inhibitors and discusses the second-generation inhibitors of this pathway. The authors propose that the way forward for the development of inhibitors of the PI3K/AKT/mTOR pathway might be a systems biology approach and biomarker-driven studies.
- Jordi Rodon
- , Rodrigo Dienstmann
- & Josep Tabernero
-
News & Views |
Cetuximab dosing by rash—is the scaling of EVEREST meaningful?
The small EVEREST trial has shown that the concept of guiding cetuximab dose escalation using the clinical parameter of acneiform skin rash is safe. However, as no significant increase of cetuximab efficacy could be observed, data from the ongoing EVEREST II trial must be awaited before dose escalation can be considered for clinical use.
- Sebastian Stintzing
- & Heinz-Josef Lenz
-
-
Review Article |
Treatment of HER2-positive breast cancer: current status and future perspectives
Despite the advent of HER2-directed therapies, many patients with HER2-positive early stage breast cancer relapse and die of this disease. Trials to define, refine and optimize the use of the approved HER2-targeted agents are ongoing. New approaches are being developed and a series of large trials in the adjuvant and neoadjuvant settings are planned or in progress. In this Review, Arteaga et al. describe the current treatment for HER2-positive breast cancer and provide an update on ongoing clinical trials and translational research.
- Carlos L. Arteaga
- , Mark X. Sliwkowski
- & Luca Gianni
-
-
Opinion |
Personalized cancer medicine—advances and socio-economic challenges
The use of therapy that is truly targeted to the needs and biological requirements of an individual patient is an aim for many in the oncology field. Jackson and Sood discuss the implications of targeted therapies on patients and the health-care system and discuss methods that might be used to maximize efficiency, cost effectiveness and patient survival.
- David B. Jackson
- & Anil K. Sood
-
-
News & Views |
New treatment paradigm for locally advanced cervical cancer?
Despite the improved progression-free survival and overall survival demonstrated by cisplatin–gemcitabine chemoradiation in a phase III randomized trial in patients with stage IIB to IVA cervical cancer, the acute and chronic toxic effects urge caution before embracing this as a new treatment paradigm.
- Peter G. Rose
-
-
-
Review Article |
The biological and therapeutic relevance of mRNA translation in cancer
The translation of mRNA is a tightly regulated process that is necessary for protein synthesis, and dysregulation of this process is associated with the development and progression of cancers. This Review highlights the components of translation machinery and how alterations in these proteins and their principle upstream signaling pathways can impact on cancer. Drugs that are currently being developed to target the translational machinery are also discussed.
- Sarah P. Blagden
- & Anne E. Willis
-
-
News & Views |
Bortezomib and dexamethasone induction for multiple myeloma
An important phase III trial involving transplant-eligible patients with multiple myeloma compared bortezomib and dexamethasone (BzD) induction with the previous standard of care. BzD was associated with a higher overall response and a deeper response to therapy that translated to superior responses following high-dose therapy and autologous stem cell transplantation.
- Jacob Laubach
- & Paul Richardson
-
News & Views |
Failure of bevacizumab in early-stage colon cancer
A randomized phase III trial of patients with stage II and III colon cancer showed no benefit of adding bevacizumab to standard adjuvant oxaliplatin plus fluorouracil and leucovorin. Despite suggestive evidence of a short-term benefit, these data and other similar findings dictate that adjuvant bevacizumab should not be used in colon cancer.
- Daniel J. Sargent
-
Correspondence |
Author reply: Lenalidomide for bortezomib-resistant multiple myeloma
- Heinz Ludwig
- & Niklas Zojer
-
Correspondence |
Lenalidomide efficacy in bortezomib-resistant myeloma
- Alessandro Gozzetti
- , Rosaria Crupi
- & Monica Bocchia
-
News & Views |
200 mg/m2 melphalan—the gold standard for multiple myeloma
Palumbo and coauthors report on the results of a randomized trial comparing two doses of melphalan in patients with symptomatic multiple myeloma. Overall complete response rates, median progression-free survival and projected 5-year overall survival were significantly higher among patients receiving the higher melphalan dose. These results confirm that for this patient population melphalan 200 mg/m2 should remain the gold standard conditioning regimen.
- Sergio Giralt
-
Correspondence |
Flows and flaws in primary central nervous system lymphoma
- Andrés J. M. Ferreri
- , Gerald Illerhaus
- & Franco Cavalli
-
News & Views |
Is thalidomide combination a new option for myeloma?
Ongoing investigation into the use of thalidomide in the treatment of multiple myeloma has demonstrated efficacy as a combination treatment during induction and as maintenance therapy. Thalidomide–doxorubicin–dexamethasone combination therapy improved response rate; however, the development of drug resistance remains a concern.
- Antonio Palumbo
-
News & Views |
Biomarkers in NSCLC for selecting cetuximab therapy
A phase III trial investigated the efficacy of carboplatin and a taxane with and without cetuximab, a monoclonal antibody against EGFR, in patients with advanced non-small-cell lung cancer. This trial did not reveal an improvement in the primary end point of progression-free survival (according to an independent radiological review committee) with the addition of cetuximab to the carboplatin and taxane regimen. A retrospective investigation of potential biomarkers did not reveal any significant association between these biomarkers and cetuximab efficacy.
- Thomas E. Stinchcombe
- & Mark A. Socinski
-
Research Highlight |
Lapatinib is effective in patients with p95HER2-positive tumors
- Lisa Hutchinson
-
News & Views |
Pazopanib: carving a niche in a crowded therapeutic landscape
Encouraging data have been reported from a randomized, double-blind, phase III trial comparing pazopanib therapy to placebo in treatment-naive and cytokine-refractory patients with advanced renal-cell carcinoma. The challenge that lies ahead is determining where pazopanib fits into the crowded therapeutic algorithms for this disease.
- Sumanta Kumar Pal
- & Robert A. Figlin
-
Review Article |
Therapy with azanucleosides for myelodysplastic syndromes
The use of azanucleosides has altered the treatment paradigm of myelodysplastic syndromes. Recently, treatment with 5-azacitidine was demonstrated to prolong survival in patients with myelodysplastic syndromes for the first time. This Review discusses the potential of these forms of treatment as monotherapy and in combination, and assesses the most recent clinical data.
- Alfonso Quintás-Cardama
- , Fabio P. S. Santos
- & Guillermo Garcia-Manero
-
Review Article |
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
EGFR is one of the most studied targets in oncology, and several inhibitors have shown promising results in selected patient populations. However, intrinsic and acquired resistance to these targeted therapies is increasingly recognized. The authors of this Review describe the successful translation of EGFR inhibitors to the clinic, and highlight the mechanisms of resistance to these agents that limit their long-term efficacy. Understanding these processes will allow researchers to develop therapies that overcome resistance and ultimately lead to more successful outcomes.
- Deric L. Wheeler
- , Emily F. Dunn
- & Paul M. Harari
-
Review Article |
Metronomic chemotherapy: new rationale for new directions
Metronomic chemotherapy is the chronic administration of chemotherapeutic agents at relatively low, minimally toxic doses, and with no prolonged drug-free breaks. This type of chemotherapy inhibits tumor growth primarily through anti-angiogenic mechanisms. The latest clinical trials of metronomic chemotherapy in adult and pediatric cancer patients are discussed and the authors highlight the research efforts that need to be made to facilitate the optimal development of metronomic chemotherapy in the clinic.
- Eddy Pasquier
- , Maria Kavallaris
- & Nicolas André
-
-
-
News & Views |
Imatinib—should we have more of a good thing?
Imatinib 400 mg has been the first-line therapy for chronic myeloid leukemia (CML) since 2001 but may have been licensed at too low a dose. A recent study compared the standard dose with higher doses in patients with newly diagnosed CML and found no difference in response rates at 12 months. But, is the devil in the detail?
- Jane F. Apperley
-
News & Views |
Individualized methotrexate dosing in primary CNS lymphoma
Although high-dose methotrexate is widely accepted as the most effective chemotherapeutic agent for primary CNS lymphoma, no optimal dose or dosing strategy has been established. Researchers from the International Extranodal Lymphoma Study Group used clinical trial data to explore whether or not an area under the curve model might be useful to optimize methotrexate dosing. The results strongly suggest that effective methotrexate dose is an important variable in patient outcome.
- Lauren E. Abrey
-
-
Case Study |
A case of variant angina in a patient under chronic treatment with sorafenib
A 63-year-old male patient under chronic treatment with sorafenib for an unresectable multifocal hepatocellular carcinoma (HCC) presented with suspected variant angina. Spontaneous spasm occurred during cardiac catheterization and was revealed during coronary angiogram with the unusual feature of a retrograde transient filling of a contralateral branch. Italo Porto and colleagues contend that the effects of sorafenib treatment were primarily responsible for the major cardiovascular event observed in this case, and suggest that clinicians should be aware of this possible severe complication of sorafenib therapy.
- Italo Porto
- , Andrea Leo
- & Filippo Crea
-
-
Research Highlight |
NPI-0052 and lenalidomide trigger apoptosis in multiple myeloma cells
- Rowan Higgs
-
-
News & Views |
Current drugs still have potential in advanced ovarian cancer
Dose-dense administration of paclitaxel as well as intraperitoneal administration of platinum and paclitaxel as first-line treatments provide similar advantages compared with standard treatment in advanced ovarian cancer. Both approaches, however, need to be confirmed by additional studies. A low dose of pegylated liposomal doxorubicin combined with carboplatin is superior to standard paclitaxel and carboplatin in relapsed platinum-sensitive ovarian cancer.
- Thomas Hogberg
-
Review Article |
Conscripts of the infinite armada: systemic cancer therapy using nanomaterials
The first generation of anti-cancer agents using novel nanomaterials has successfully entered widespread use and newer nanomaterials are gaining increasing interest as potential multifunctional therapeutic agents. The authors of this Review discuss how the new features of these agents could potentially allow increased cancer selectivity, changes in pharmacokinetics, amplification of cytotoxic effects, and simultaneous imaging capabilities.
- David A. Scheinberg
- , Carlos H. Villa
- & Michael R. McDevitt
-
Review Article |
mTOR signaling and drug development in cancer
Mammalian target of rapamycin (mTOR) has a key role in several pathways that are involved in cell growth and cancer. In this Review, Dr. Dancey outlines the mechanisms of action and performance of current mTOR inhibitors in clinical trials. Second-generation inhibitors are also discussed along with strategies that should be used to improve outcomes achieved with mTOR inhibitors.
- Janet Dancey
Browse broader subjects
Browse narrower subjects
- Biocatalysis
- Biophysical chemistry
- Biosynthesis
- Carbohydrates
- Chemical ecology
- Chemical genetics
- Chemical libraries
- Chemical modification
- Chemical tools
- Cheminformatics
- Combinatorial libraries
- Computational chemistry
- DNA
- Drug delivery
- Enzyme mechanisms
- Enzymes
- Glycobiology
- Glycomics
- Ion channels
- Kinases
- Lipidomics
- Lipids
- Mechanism of action
- Membranes
- Metabolic pathways
- Metabolomics
- Metals
- Natural products
- Networks and systems biology
- Nucleic acids
- Peptides
- Pharmacology
- Post-translational modifications
- Proteases
- Protein design
- Protein folding
- Proteins
- Proteomics
- RNA
- Screening
- Small molecules
- Synthetic biology
- Target identification
- Target validation
- Transporters